- All
- Event Participitation (3)
- News & Press releases (2)
- Scientific Publication (2)
Event Participitation
Meet Cycuria at ASH Annual Meeting 2024 in San Diego
Cycuria will be attending the upcoming American Society of Hematology (ASH) Annual Meeting in San Diego from December 7- December 10. We look forward to...
News & Press releases
Cycuria Founder, Prof. Dr. Philipp Jost, Highlights the Strategic Advantages and Opportunities at Medical Science City Graz
We’re thrilled to share recent press coverage highlighting Cycuria Therapeutics‘ innovative approach in oncology and our choice to establish roots in Graz’s Medical Science City,...
News & Press releases
Cycuria Featured in the Austrian National Newspaper Die Presse
Die Presse, one of Austria’s most respected national newspapers, features our scientific breakthrough in cancer research led by our scientific founder, Prof. Dr. Philipp Jost....
Event Participitation
Cycuria to Present at the Upcoming BIO-Europe Partnering Conference in Stockholm
Cycuria will be participating at the upcoming BIO-Europe partnering event in Stockholm, Sweden from 4th-6th Nov. Reach out to schedule one-on-one meeting with our CEO...
Scientific Publication
XIAP discriminates between type I and type II FAS-induced apoptosis. Nature 2009
XIAP discriminates between type I and type II FAS-inducedapoptosis. Nature 2009
Scientific Publication
RIPK3 Restricts Myeloid Leukemogenesis
RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death andDifferentiation of Leukemia Initiating Cells. Cancer Cell. 2016